SLDB vs DNA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SLDB · Solid Biosciences$6.59 ▲ 6.63%
DNA · Ginkgo Bioworks$11.29 ▲ 13.35%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SLDB +58.8%
- DNA +28.7%
Head to head
| Metric | SLDB | DNA |
|---|---|---|
| Price | $6.59 | $11.29 |
| Change today | ▲ 6.63% | ▲ 13.35% |
| Market cap | $735.51M | $760.27M |
| Return, 3 months | -23.0% | +47.6% |
| Return, year to date | +16.8% | +35.9% |
| Return, 1 year | +62.3% | +26.1% |
| P/E (TTM) | – | – |
| P/B | 2.2 | 1.9 |
| P/E percentile vs own 5y | 12th | 32nd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -48.5% |
| Net profit growth (YoY) | -38.8% | +22.5% |
| Gross margin | – | 68.0% |
| Operating margin | – | -228.6% |
| Net margin | – | -219.6% |
| Return on equity | -65.5% | -56.3% |
| Analyst target vs. price | +203.5% | -38.0% |
| Analyst buy share | 100% | 0% |
| RSI (14) | 50 | 52 |
| 30-day volatility | 75.0% | 157.2% |
| Max drawdown, 1 year | -51.0% | -59.1% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Sell |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DNA is the largest of the group by market value.
- SLDB has returned the most over the past year.
- SLDB has been the calmest stock over the last 30 days.